← back to search

Yolande Du Toit

Roche (Switzerland) · CH
Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, and Advanced Breast Cancer Therapies.
h-index
4
citations
243
works
12
NIH funding
primary concept
Medicine
email

Recent publications

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Annals of Oncology 2021cited by 86position: middledoi
Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2021cited by 1position: middledoi
288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Annals of Oncology 2020cited by 3position: middledoi
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Annals of Oncology 2019cited by 113position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mario Campone · Centre de Recherche en Cancérologie de Lyon2 papers (2020–2021)Valentine Revelant · Roche (Switzerland)2 papers (2020–2021)Eva Ciruelos · Breast Cancer Research Foundation2 papers (2020–2021)Andreas Schneeweiß · NSABP Foundation2 papers (2020–2021)Tamar Peretz‐Yablonski · Hebrew University of Jerusalem2 papers (2020–2021)Shani Paluch–Shimon · Hebrew University of Jerusalem2 papers (2020–2021)Hassan Errihani · Ibn Sina Hospital2 papers (2020–2021)Fabio Puglisi · University of Udine2 papers (2020–2021)Igor Bondarenko · Dnipro State Medical University2 papers (2020–2021)Thomas Bachelot · Hôpital Léon Bérard2 papers (2020–2021)Zbigniew Nowecki · Institute of Cardiology2 papers (2020–2021)Dirk Klingbiel · Bristol-Myers Squibb (Switzerland)2 papers (2020–2021)Andrew Wardley · University of Manchester2 papers (2020–2021)Jean-Louis Merot · IQVIA (France)1 papers (2020–2020)D.W. Miles · Mount Vernon Cancer Centre1 papers (2020–2020)David Miles · PsiOxus Therapeutics (United Kingdom)1 papers (2021–2021) · 1 papers (2021–2021)